Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2020-08-03 09:30:09[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2
-
FDA Approves Daiichi Sankyo’s TURALIO® (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating TumorDaiichi Sankyo2020-08-03 09:31:50FDA Approves Daiichi Sankyo’s TURALIO® (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare
-
Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AMLDaiichi Sankyo2020-08-03 09:32:24Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML
